GLP-1 Medication and Eating Disorder History: What to Ask Before You Start

A double-edged mechanism, named plainly by the field itself

Eating disorders are not a footnote for this population — lifetime prevalence in U.S. adults runs meaningfully higher in women than men across nearly every diagnosis, from anorexia and bulimia to binge eating disorder⁴, and global estimates in young people show the same skew⁵. A 2026 "Spotlight" article in the *International Journal of Eating Disorders* — written to name a gap the field has been slow to address — put the core tension in plain terms: GLP-1 receptor agonists may hold real therapeutic promise for binge eating disorder, but the same mechanisms that reduce appetite and food preoccupation can also reinforce restriction, avoidance of regular eating, compulsive weight control and relapse in people vulnerable to those patterns¹. That is not a reason to treat every prospective patient with suspicion. It is a reason routine screening should exist before prescribing, and the same review found that in current practice, it usually doesn't¹.

The promising side: binge eating disorder

The most encouraging evidence here is specific to binge eating disorder (BED), not eating disorders broadly. A systematic review of GLP-1 receptor agonists as pharmacotherapy for binge eating and bulimia nervosa found consistent reductions in binge frequency across the studies reviewed², and a 2026 review of incretin-based therapies for binge eating reached a similar conclusion — early trial and observational data suggest real benefit for the loss-of-control eating that defines BED³. If binge eating is the pattern you're bringing to a GLP-1 conversation, that is meaningfully different from a restrictive-eating history, and it is worth saying so directly to a prescriber rather than letting "eating disorder history" get treated as one undifferentiated red flag.

The riskier side: restrictive and body-image-driven eating

The concern runs the other direction for anyone with a history of anorexia nervosa, atypical anorexia, or a strong pattern of restriction and compulsive weight control. A medication whose entire mechanism is reducing hunger and food preoccupation removes one of the body's own signals that a restrictive pattern is starting to compound — the same signal that, for someone without that history, is simply appetite suppression working as intended. The 2026 Spotlight review proposed six concrete practice priorities for the field: routine eating-disorder screening before and during treatment, risk stratification, validated monitoring tools built for this specific risk, a discontinuation plan agreed in advance, incorporating patient lived experience into guidelines, and communication that reduces weight stigma without minimizing metabolic health goals¹. Most of that is aspirational for the field right now — but it is also a usable checklist for what a genuinely careful provider should already be doing.

Questions worth asking before you start

Has this program asked about eating-disorder history at all, beyond a checkbox? If you've had binge eating disorder, does the plan include therapy or behavioral support alongside the medication, rather than treating the drug as a complete solution on its own? If you've had any history of restriction, has anyone discussed what "too much appetite suppression" would look like for you specifically, and at what point you'd pause treatment? Our guide to protein and intake as a modifiable amplifier of GLP-1 side effects covers a related pattern — under-eating on a GLP-1 is easy to fall into even without a prior eating-disorder history, which is one more reason deliberate nutrition support matters regardless of your background. And this is exactly the kind of intake-level care our guide to choosing a GLP-1 provider is built around — a program that only asks about your BMI is not the same as one that asks about your relationship with food. This guide is educational only and not medical advice; if you have a current or past eating disorder, loop in a clinician with eating-disorder expertise before starting or continuing any GLP-1 medication.